Prolight announces positive data from patient blood study at St Thomas’ Hospital, London
Data from St Thomas’ Hospital have confirmed equivalence between whole blood and plasma from patients with elevated troponin levels. The study is a key stepping-stone between the successful biobank study earlier this year and the planned clinical study for product approval. “These initial results from St Thomas’ Hospital are highly encouraging and exactly what we […]
Prolight publishes information document in connection with rights issue of shares
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Extraordinary general meeting of Prolight Diagnostics AB (publ) on 10 June 2025
The extraordinary general meeting (EGM) of Prolight Diagnostics AB (publ) (the “Company”) took place on 10 June 2025 in Lund. The EGM resolved in accordance with the proposals by the board of directors. The main content of the main resolutions is described below. Resolution on approval of the board of directors’ resolution to issue shares […]
The future of Point of Care Analysis – Right Here, Right Now
Prolight Diagnostics has developed a breakthrough point-of-care system that delivers reliable test results in 10 minutes or less, right at the patient´s side. Driving efficiency and accelerating time to clinical decision. Watch the video (https://youtu.be/WVNC8vKRdWA) to discover why our proprietary, patent-protected technology is at the heart of the next major shift in healthcare. For further information, please […]
Prolight announces additional subscription commitments and a lock-up commitment for upcoming rights issue of shares
Prolight Diagnostics (“Prolight” or the “Company”) hereby announces that additional existing shareholders and external investors have submitted subscription commitments totaling 2.9 MSEK for the upcoming rights issue of shares (the “Rights Issue”) that Prolight resolved on, subject to approval by the subsequent extraordinary general meeting, on May 21, 2025. Including these new subscription commitments, the […]
Prolight Diagnostics AB (publ) publishes annual report for 2024
Prolight Diagnostics AB (publ) announces that the annual report for 2024 is now available on the company’s website: https://prolightdx.com/en/investors/financial-reports/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic […]
Prolight Diagnostics publishes quarterly report Q1, 2025
Financial overview First quarter, January 1 – March 31, Q1 2025 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to 1,662 (68) thousand SEK. Profit after tax amounted to -10,937 (-8,929) thousand SEK. Earnings per share before and after dilution: -0.02 […]
Biostock publishes article about the positive pre-clinical results and coming milestone for Prolight Diagnostics in Q2
Prolight’s CSO reflects on positive pre-clinical results and looks ahead to the next key milestone in Q2: Read the article here: https://biostock.se/2025/05/prolights-cso-reflects-on-positive-pre-clinical-results-and-looks-ahead-to-key-milestone-in-q2/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing […]
NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), corp. reg. no. 556570-9499, (the ”Company”) are hereby notified of the annual general meeting to be held on Monday 30 June 2025 at 1 p.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification of attendance Shareholders who wish to participate in the annual general […]
Emergers publishes updated analysis about Prolight Diagnostics
Emergers publishes updated analysis about Prolight DIagnostics with the title: ”Gearing up for commercialisation with strong insider backing”. Among others, the article describes ”Strong insider commitment signals confidence” and that Prolight is ”Well-positioned for strategic partnering in 2025” Read the article here: https://www.emergers.se/prolight-j25/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: […]
